Misoprostol vaginal insert

Drug Profile

Misoprostol vaginal insert

Alternative Names: Misodel; Misopess; Misoprostol CR insert; MVI 100; Mysodelle; Myspess; XP 16J

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokine PharmaSciences
  • Developer Cytokine PharmaSciences; Ferring Pharmaceuticals
  • Class Abortifacients; Antiulcers; Oxytocics; Prostaglandins
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Labour induction

Most Recent Events

  • 09 May 2016 Launched for Labour induction in Israel (Vaginal) before May 2016
  • 09 Sep 2015 No recent reports on development identified - Phase-III for Labour induction in Canada (Vaginal)
  • 09 Sep 2015 No recent reports on development identified - Preregistration for Labour induction in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top